869 results about "Galactosucrose" patented technology

A conjugate of formula A-L-P, in which:A represents a glycosylated / galactosylated peptide that binds to a cell-surface receptor,L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalently bonded to A and P in a regiospecific manner, andP represents a monomer, homopolymer or heteropolymer comprising at least one nucleotide or an analogue thereof, which inhibits the intracellular biosynthesis of nucleotides or nucleic acids in a sequence-independent manner,wherein either or both of the covalent bond between A and L and the covalent bond between L and P can be cleaved intracellularly; a composition comprising such a conjugate; and a method of inhibiting abnormal cellular proliferation in a mammal; and a method of inhibiting replication of a virus in a mammal.

An improved process for chlorination of sugars produces chlorodeoxy derivatives, in particular the chlorination of sucrose-6-esters to produce sucralose (4,1′,6′-trichloro-4,1′,6′-trideoxy galactosucrose), with thionyl chloride and N,N-dimethyl formamide (DMF) at the ration of about 1 molar equivalent of thionyl chloride for every molar equivalent of free hydroxyl group.

Shampoo compositions comprise (a) from about 5% to about 50% of one or more detersive surfactants; (b) a dispersed gel network phase comprising: (i) at least about 0.05% of one or more fatty amphiphiles; (ii) at least about 0.01% of one or more secondary surfactants; and (iii) water; (c) at least about 0.05% of a galactomannan polymer derivative with a net positive charge and having a mannose to galactose ratio of greater than 2:1 on a monomer to monomer basis, wherein the galactomannan polymer derivative has: (i) a molecular weight from about 1,000 to about 10,000,000; and (ii) a cationic charge density from about 0.7 meq / g to about 7 meq / g; and (d) at least about 20% of an aqueous carrier; all by weight of the shampoo composition.

A hair conditioning composition comprising:a) from about 0.01 wt. % to about 10 wt. % of a non-guar galactomannan polymer derivative having a mannose to galactose ratio of greater than 2:1 on a monomer to monomer basis, said non-guar galactomannan polymer derivative selected from the group consisting of a cationic non-guar galactomannan polymer derivative and an amphoteric non-guar galactomannan polymer derivative having a net positive charge;i. wherein said non-guar galactomannan polymer derivative has a molecular weight from about 1,000 to about 10,000,000; andii. wherein said non-guar galactomannan polymer derivative has a cationic charge density from about 0.7 meq / g to about 7 meq / g;b) a conditioning agent selected from the group consisting of cationic surfactants, cationic polymers, nonvolatile silicones, nonvolatile hydrocarbons, saturated C14 to C22 straight chain fatty alcohols, nonvolatile hydrocarbon esters, and mixtures thereof; andc) wherein said hair conditioning composition is substantially free of an anionic surfactant.

The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and / or within the central nervous system in a subject. A final aspect of the invention provides a method of treating a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a rhASA and thereby obtaining a reduction in the galactosyl sulphatide levels in target cells within said subject.

The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.

Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.

A poultry feed composition including protein, vitamins and minerals, and a source of carbohydrates from the group consisting of soybean meals and corn supplemented with an alpha-galactosidase that catalyzes the degradation of the galactoside. The addition of the alpha-galactosidase increases the ratio of gain to feed, increases the amount of white meat, or decreases the amount of fat deposited during growth of a chicken fed the feed composition, relative to the chicken fed on an identical feed composition absent the alpha-galactosidase.

The invention encompasses the use of a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida in various methods and uses, wherein said lipolytic enzyme is capable of hydrolysing a glycolipid or a phospholipid or transferring an acyl group from a glycolipid or phospholipids to an acyl acceptor. Preferably, the lipolytic enzyme for use in these methods and uses comprises an amino acid sequence as shown in any one of SEQ ID NOs: 4, 5, 7, 8, 12, 14 or 16 or an amino acid sequence having at least 70% identity therewith or comprises a nucleotide sequence shown as SEQ ID NO: 3, 6, 9, 13, 15 or 17 or a nucleotide sequence which has at least 70% identity therewith. The present invention also relates to a lipolytic enzyme capable of hydrolysing at least a galactolipid or capable of transferring an acyl group from a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable from Streptomyces species and includes a lipolytic enzyme comprising an amino acid sequence as shown in SEQ ID NO: 4 or an amino acid sequence which has at least 60% identity thereto. The enzyme may be encoded by a nucleic acid selected from the group consisting of: a) a nucleic acid comprising a nucleotide sequence show in SEQ ID NO: 3; b) a nucleic acid which is related to the nucleotide sequence of SEQ ID NO: 3 by the degeneration of the genetic code; and c) a nucleic acid comprising a nucleotide sequence which has at least 70% identity with the nucleotide sequence shown in SEQ ID NO: 3.

The present disclosure generally relates to pediatric nutritional compositions including a prebiotic mixture of galacto-oligosaccharide and / or polydextrose, a probiotic, such as Lactobacillus rhamnosus GG, and human milk oligosaccharides. More particularly, the present disclosure relates to a nutritional composition having: (i) a protein source, (ii) a lipid source, (iii) a carbohydrate source, (iv) a human milk oligosaccharide or a precursor thereof, (v) polydextrose and / or galacto-oligosaccharides, and (vi) a probiotic. The disclosed nutritional compositions advantageously promote the gut-brain axis.

An obesity control agent with health-restorative and health-promotional benefits to humans comprising the extract of Chlorophytum species, more particularly, Chlorophytum arundinacceum, is disclosed. The bioactive principles responsible for anti-obesity property have been determined to be mainly due to spirosta-steroidal saponins, spirosta-steroidal alkaloids and galacto-glucan oligosaccharides. Most effective as an obesity control agent is the spirosta-steroidal saponins. Pharmaceutical, nutritional and veterinary use of this inventive composition is also disclosed.

A feed additive composition comprising a direct fed microbial (DFM), in combination with a xylanase (e.g. endo-1,4-β-d-xylanase) and a β-glucanase (and optionally a further fibre degrading enzyme), wherein the DFM is selected from the group consisting of an enzyme producing strain; a C5 sugar-fermenting strain; a short-chain fatty acid-producing strain; a fibrolytic, endogenous microflora-promoting strain; or combinations thereof. The DFM may be selected from the group consisting of: Bacillus subtilis AGTP BS3BP5, Bacillus subtilis AGTP BS442, B. subtilis AGTP BS521, B. subtilis AGTP BS918, Bacillus subtilis AGTP BS1013, B. subtilis AGTP BS1069, B. subtilis AGTP 944, B. pumilus AGTP BS 1068 or B. pumilus KX11-1, Enterococcus faecium ID7, Propionibacterium acidipropionici P169, Lactobacillus rhamnosus CNCM-1-3698, Lactobacillus farciminis CNCM-1-3699, a strain having all the characteristics thereof, any derivative or variant thereof, and combinations thereof and the further fibre degrading enzyme may be selected from the group consisting of a cellobiohydrolase (E.C. 3.2.1.176 and E.C. 3.2.1.91), a β-glucosidase (E.C. 3.2.1.21), a β-xylosidase (E.C. 3.2.1.37), a feruloyl esterase (E.C. 3.1.1.73), an α-arabinofuranosidase (E.C. 3.2.1.55), a pectinase (e.g. an endopolygalacturonase (E.C. 3.2.1.15), an exopolygalacturonase (E.C. 3.2.1.67) or a pectate lyase (E.C. 4.2.2.2)), or combinations thereof.

The invention relates to a colloid bismuth pectin compound and a quality control method of pharmaceutical compositions of the colloid bismuth pectin compound, and specifically provides a colloid bismuth pectin compound, new quality control indexes of pharmaceutical compositions of the colloid bismuth pectin compound and a detection method of the colloid bismuth pectin compound and the pharmaceutical compositions of the colloid bismuth. In the prior art, the quality of products having poor efficacy can not be well controlled because the efficacy-related indexes are not controlled strictly in the existing quality control methods of colloid bismuth pectin and pharmaceuticals thereof. Based on the existing quality control methods of colloid bismuth pectin and pharmaceuticals thereof, the following detection items and indexes are added: intrinsic viscosity, gel property, uniformity and galacturonic acid content. The invention can effectively ensure clinical efficacy of products, make the product quality standards more scientific, reasonable and controllable, and has great significance in quality control of the colloid bismuth pectin and the pharmaceutical preparation of colloid bismuth pectin.

The invention relates to a bactericide composition containing oligosaccharide and copper. The composition is characterized by being prepared from main active ingredients such as oligosaccharide and a copper preparation and pesticide auxiliaries and comprising the following components in percentage by weight: 1-45% of oligosaccharide, 1-50% of copper preparation and the balance of pesticide auxiliaries, wherein the oligosaccharide is one of amino-oligosaccharin (chitosan oligosaccharide), oligogalacturonide acid (pectic oligosaccharide, oligosaccharin) and sodium alginate oligosaccharide; the copper preparation is an inorganic copper or organic copper bactericide; and the dosage form of the bactericide composition can be water agents, emulsion in water, wettable powder, water dispersible granules, suspensions, granules, paste or microcapsule sustained-release agents. The composition has the following beneficial effects: the drug resistance of crops is overcome and delayed; the disease resistance of the crops is improved; the composition can generate synergy together with chemical bactericides; and the composition is safe in application and is safe to the environment and people.

The invention relates to a process of recovering arabinose and optionally other monosaccharides from vegetable fiber rich in heteropolymeric arabinose, such as gum arabic. Said other monosaccharides are typically selected from galactose and rhamnose. The process of the invention comprises controlled hydrolysis of the arabinose-rich vegetable fiber and fractionation of the hydrolysis product to obtain a fraction enriched in arabinose and optionally other product fractions followed by crystallization of arabinose. The invention also relates to a novel method of crystallizing arabinose from biomass-derived material. Furthermore, the invention relates to novel crystalline L-arabinose.

Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and / or galactooligosaccharides.

The invention discloses two types of flavonoid glycoside compounds which are kaempferol-3-O-[alpha-L-rhamnopyranosyl-(1-3)-(2'' ', 4'' '-O-diacetyl-alpha-L-rhamnopyranosyl)-(1-6)]-beta-glucopyrose galactopyranoside and kaempferol-3-O-[alpha-L-rhamnopyranosyl-(1-3)-(4'' '-O-acetyl-alpha-L-rhamnopyranosyl)-(1-6)]-beta-D-glucopyrose galactopyranoside respectively. The invention also discloses a method for preparing the two types of flavonoid glycoside compounds. Moreover, pharmacological tests prove that the two types of flavonoid glycoside compounds have quite good effects of reducing blood sugar and blood fat and resisting oxidation and cerebral ischemia, and thus, the flavonoid glycoside compounds of the invention can be used for preparing medicaments, food and cosmetics for preventing and treating diabetes, reducing blood fat and resisting oxidation and cerebral ischemia.

The invention relates to a new application of low molecular citrus pectin, in particular to the application of low molecular citrus pectin for treating and preventing lead and heavy metal poisoning in prepared medicines, foods and health care products. The low molecular citrus pectin is a compound prepared from soluble dietary fiber and galacturonic acid, the polysaccharide derivative is used as a metal ion absorbent (chelating agent), has absorption action on heavy metal ions, can remove heavy ions, such as Zn2+, Cu2+, Cd2+, Ag+, Cr3+, Ni2+, Hg2+, Pb2+ and the like. The low molecular citrus pectin is different from common chemical chelating agents; proved by animal and clinic experiments, lead, mercury and arsenic are discharged out of human bodies during toxin discharge, and the key level of calcium, magnesium, zinc or other minerals can not be influenced. The natural chelating function of the low molecular citrus pectin is a most ideal and successful solution for heavy metal pollution in the human body at present. Thus, the low molecular citrus pectin has the function of preventing various diseases and especially has special functions of clearing away harmful cells and discharging toxins in the human body.

The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+ / -0.3): (1+ / -0.3): (3.5+ / -0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and / or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and / or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.

An object of the invention is to develop galactose or mannose derivatives of docetaxel, etc. having improved solubility and physiological activity, to alleviate burden imposed on patients and to provide effective therapeutic drug for tumors.The present invention provides taxoid derivatives comprising any of paclitaxel, docetaxel and 10-deacetyl-baccatin III to which galactose or mannose is linked through a spacer, and methods for producing taxoid derivatives comprising reacting paclitaxel, docetaxel or 10-deacetyl-baccatin III with tetrabenzyl acetyloxygalactoside or tetrabenzyl acetyloxymannoside, subjecting the product to debenzylation reaction, and optionally to detriethylsilylation reaction.

The invention discloses a method for improving yield of salvianolic acid B in savia miltiorrhiza suspension culture cells by inducing, specifically comprising the following steps: 1) cultivating the aseptic seedlings; 2) inducing the callus; 3) sub-cultivating the callus; 4) cultivating the callus by suspending; 5) inducing to produce the salvianolic acid B; and 6) harvesting the culture cells. The method solves the problem that the salvianolic acid B is not produced after the inducing factors, such as yeast extract, galacturonic acid, mycelia extract and the like are added. The content of the salvianolic acid B in the savia miltiorrhiza suspension culture cells is increased by about 5 times by using the method. The technology condition provided by the invention is suitable for industrial production of the salvianolic acid B on a large scale by a cell culture method after being expanded.

The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3.GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.

The invention discloses a micro-ecological composition for improving constipation by targeting intestinal flora and a preparation of the micro-ecological composition. The micro-ecological compositioncomprises probiotics, prebiotics and medicinal and edible traditional Chinese medicines, wherein the probiotics are selected from at least one of bifidobacterium animalis, bifidobacterium adolescentis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactobacillus acidophilus, lactobacillus helveticus, lactobacillus plantarum, lactobacillus reuteri, lactobacillus paracasei and bacillus coagulans; the prebiotics are selected from at least one of stachyose, fructo-oligosaccharide, isomalto-oligosaccharide, galacto-oligosaccharide, inulin, resistant dextrin and xylooligosaccharide; and the medicinal and edible traditional Chinese medicines are selected from at least one of semen sesami nigri, semen cassiae, fructus cannabis, honey, semen lablab album, semen coicis, poria cocos and lotus leaves. The micro-ecological composition can effectively regulate intestinal tract micro-ecology in a targeted mode, and finally the purpose of improving constipation is achieved.

Methods for providing transgenic plants and parts hereof that, relative to the wild type state, is modified in a complex cell wall polysaccharide structure including pectins and hemicelluloses, the modification being in the overall glycosidic linkage pattern or the monosaccharide profile, comprising transforming a plant cell with a nucleotide sequence that causes an altered production of a complex cell wall polysaccharide-modifying enzyme such as endo-rhamnogalacturonan hydrolase, an endo-rhamnogalacturonan lyase, an endo-galactanase, an endo-arabinanase, an arabinofuranosidase, a galactosidase such as a beta-galactosidase, a xylosidase and an exo-galacturosidase. The modification can occur in vivo or post harvest, in which latter case the modifying enzyme is separated in the growing plant from its substrate, e.g. by targeting the enzyme to the Golgi, the endoplasmic reticulum or a vacuole, or is in a form that is inactive in the plant. After harvest the enzyme is brought into contact with its substrate or it is activated to provide the desired post harvest modification of the cell wall polysaccharide. The transgenic plant materials have improved functionalities and are useful in food and feed manufacturing and as pharmaceutically or medically active substances.

Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula:

The present invention relates to skin care compositions providing a method of enhancing the remodeling of age damaged and sun damaged skin in mammals utilizing an elastin peptide (EP) ligand of the general formula (GXXPG)n and in particular the sequences of (VGVAPG)n and / or (GVAPGV)n, and / or (VAPGVG)n and / or (APGVGV)n and / or (PGVGVA)n and / or (GVGVAP)n and a galactosugar which modulates the effect of the elastin peptide ligand(EP) on its lectin the Elastin-Binding Receptor (EBR). wherin A is a peptide-forming residue of L-alanine; G is a peptide-forming residue of glycine P is a peptide-forming residue of L-proline V is a peptide-forming residue of L-valine X is a peptide-forming residue of a single unspecified amino acid Peptide representations in this application conform to the standard practice of writing the NH2-terminal amino acid residue at the left of the formula and the CO2 H-terminal amino acid residue at the right.

The invention discloses a composite prebiotics which is composed of fructooligosaccharid and inulin of which the mixture ratio is 1:0.1 to 10 or oligomeric galactose, the fructooligosaccharid and the inulin all of which the mixture ratio is 0.1 to 10:1:0.1 to 10. The composite prebiotics overcomes the shortcoming that the single component of the prebiotics cannot fully exert the physiological efficacy, solves the technical problem that bifidobacterium and lactobacillus are proliferated rapidly and efficiently and the efficacy of the Prebiotics perforates through each end of the colon, particularly, the conventional liquid prebiotics is made into powder, so that the quality of products is more stable and the use is more convenient. The composite prebiotics is a high-quality composite prebiotics which can completely improve the component of probiotics in the intestines and fast, continuously and effectively proliferate the probiotics.

The invention discloses a probiotics-Chinese herbal medicine compound composition capable of loosening bowels to relieve constipation and application of the probiotics-Chinese herbal medicine compoundcomposition and belongs to the technical field of health-care foods. The composition comprises 13-15 kinds of lactobacillus rhamnosus, lactobacillus plantarum, lactobacillus paracasei, bifidobacterium lactis, lactobacillus acidophilus, bifidobacterium longum, lactobacillus reuteri, lactobacillus helveticus, lactobacillus fermentum, lactobacillus johnsonii, lactobacillus casei, lactobacillus crispatus, bifidobacterium breve, bifidobacterium bifidum and bifidobacterium infantis, 10-13 kinds of isomalto-oligosaccharide, inulin, lactitol, stachyose, fructo-oligosaccharide, xylo-oligosaccharide, Mannan-oligosaccharide, galacto-oligosaccharide, oat beta-glucan, glucan, soluble soybean polysaccharide, resistant dextrin and chitosan-oligosaccharide and 2-4 kinds of malts, fructus crataegi, blackplums and fermented soybeans. According to the probiotics-Chinese herbal medicine compound composition and the application thereof, probiotics, prebiotics and traditional Chinese medicine powder are compounded and can jointly promote intestinal canal health.

Disclosed is a novel ss-galactosidase. Specifically disclosed are a ss-galactosidase derived from Bacillus circulans and a gene for the ss-galactosidase. The ss-galactosidase can be used, for example, in the production of milk, dairy products, fermented dairy products, galacto-oligosaccharides or supplements for foods.

The invention discloses a composition for improving the intestinal microecology and preventing a chronic disease. The composition is prepared from inulin, galactooligosaccharide and composite dietary fiber, wherein the ratio of the inulin to the galactooligosaccharide to the composite dietary fiber is (1 to 75) to (1 to 75) to (5 to 95), and preferably (10 to 50) to (10 to 50) to (25 to 50). The invention further discloses balanced nutrition food containing the composition. The balanced nutrition food comprises cereal meal; and the ratio of the cereal meal to the composition is (50 to 95) to (50 to 5), and preferably (70 to 95) to (30 to 5). The composition can retain moderate survival of non probiotics through common glycan; a functional glycan prebiotics combination can promote growth of probiotics; and by the synergistic effect among glycans, stable equilibrium of intestinal microorganisms can be maintained, the intestinal flux, endotoxins and inflammatory factors are reduced, the immunity is enhanced, and the chronic disease is prevented. The balanced nutrition food can provide balanced nutrition for superorganisms, improve the subhealth and prevent the chronic disease.